A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy.
Oncotarget. 2017 Jul 12;:
Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study.
Clin Lymphoma Myeloma Leuk. 2017 Jun 29;:
Establishing an autologous versus allogeneic hematopoietic cell transplant program in nations with emerging economies.
Hematol Oncol Stem Cell Ther. 2017 Jul 03;:
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
Haematologica. 2017 Feb;102(2):327-335
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
Haematologica. 2016 Sep;101(9):1065-73
Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.
Leuk Lymphoma. 2017 Jun 09;:1-4
Extramedullary disease at diagnosis of AML does not influence outcome of patients undergoing allogeneic hematopoietic cell transplant in CR1.
Eur J Haematol. 2017 May 27;:
Long Term Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: a Single Center Experience.
Biol Blood Marrow Transplant. 2017 Feb 27;:
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
J Hematol Oncol. 2017 Feb 22;10(1):55